Peak serum C-reactive protein concentrations were measured in 146 patients randomized to receive streptokinase, alteplase, or a combination of streptokinase and alteplase in the GUSTO-I trial. Those receiving alteplase treatment had lower values than those receiving streptokinase or the combination treatment. Irrespective of treatment, complete reperfusion of the infarct-related artery (TIMI grade 3 flow) was associated with low peak serum C-reactive protein values.

9007-41-4 (C-Reactive Protein), Aged, C-Reactive Protein/*metabolism, Comparative Study, Drug Therapy, Combination, EC 1.1.1.30 (Hydroxybutyrate Dehydrogenase), EC 3.4.- (Streptokinase), EC 3.4.21.68 (Tissue Plasminogen Activator), Female, Human, Hydroxybutyrate Dehydrogenase/*blood, Male, Middle Aged, Myocardial Infarction/*blood/drug therapy, Streptokinase/*therapeutic use, Support, Non-U.S. Gov't, Tissue Plasminogen Activator/*therapeutic use
dx.doi.org/10.1016/S0002-9149(97)00606-1, hdl.handle.net/1765/5520
The American Journal of Cardiology
Erasmus MC: University Medical Center Rotterdam

Pietila, K, Hermens, W.T, Harmoinen, A, Baardman, T, Pasternack, A, Topol, E.J, & Simoons, M.L. (1997). Comparison of peak serum C-reactive protein and hydroxybutyrate dehydrogenase levels in patients with acute myocardial infarction treated with alteplase and streptokinase. The American Journal of Cardiology, 80(8), 1075–1077. doi:10.1016/S0002-9149(97)00606-1